An Ultra-Sensitive Immunoassay for Quantifying Biomarkers in Breast Tumor Tissue

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) have been validated at the highest level of evidence as clinical biomarkers of prognosis in breast cancer. The American Society of Clinical Oncology recommends using uPA and PAI-1 levels in breast tumors fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fowler, Carol B., Man, Yan-Gao, Mason, Jeffrey T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909766/
https://www.ncbi.nlm.nih.gov/pubmed/24494029
http://dx.doi.org/10.7150/jca.8084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909766/
https://www.ncbi.nlm.nih.gov/pubmed/24494029
http://dx.doi.org/10.7150/jca.8084

Ejemplares similares